Parasitology

cambridge.org/par

$CD14^+$ monocytes are the main leucocytic sources of CXCL10 in response to *Plasmodium falciparum*

Lisa J. Ioannidis[1,2], Emily Eriksson[1,2] and Diana S. Hansen[1,2]

[1]The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia and [2]The Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia

Research Article

Cite this article: Ioannidis LJ, Eriksson E, Hansen DS (2020). $CD14^+$ monocytes are the main leucocytic sources of CXCL10 in response to *Plasmodium falciparum*. *Parasitology* **147**, 465–470. https://doi.org/10.1017/S0031182019001744

Received: 3 October 2019
Revised: 25 November 2019
Accepted: 3 December 2019
First published online: 13 December 2019

Key words:
Chemokines; malaria; monocytes; pathogenesis

Author for correspondence:
Diana S. Hansen, E-mail: hansen@wehi.edu.au

Abstract

The CXCR3 chemokine CXCL10 or IFN-γ inducible protein 10 (IP-10) has been identified as an important biomarker of cerebral malaria (CM) mortality in children. Studies in mouse malaria infection models have shown that CXCL10 blockade alleviates brain intravascular inflammation and protects infected mice from CM. Despite the key role that CXCL10 plays in the development of CM, the leucocytic sources of CXCL10 in response to human malaria are not known. Here we investigated CXCL10 responses to *Plasmodium falciparum* in peripheral blood mononuclear cells (PBMCs). We found that PBMCs from malaria-unexposed donors produce CXCL10 in response to *P. falciparum* and that this response is IFN-γ-dependent. Moreover, $CD14^+$ monocytes were identified as the main leucocytic sources of CXCL10 in peripheral blood, suggesting an important role for innate immune responses in the activation of this pathway involved in the development of symptomatic malaria.

Introduction

Malaria is a mosquito-borne infectious disease that is responsible for more than 200 million clinical cases and 400 000 deaths annually (WHO, 2016). Although there are five species of *Plasmodium* that can infect humans, most cases of severe malaria are caused by *Plasmodium falciparum*. Cerebral malaria (CM) is one of the most severe complications of *P. falciparum* infection, with a case fatality rate of approximately 20% even with appropriate medical treatment (Murphy and Breman, 2001). Blood-stage malaria parasites express proteins on the surface of the infected red blood cell, which allows them to bind to vascular endothelial cells and avoid clearance in the spleen. This process, known as sequestration, induces obstructions in the blood flow, resulting in hypoxia and haemorrhages (Miller *et al.*, 2002), associated with the induction of organ-specific disease syndromes (Walter *et al.*, 1982; Turner *et al.*, 1994; Grau *et al.*, 2003; Taylor *et al.*, 2004). A large body of work indicates that inflammatory responses also contribute to severe disease (Molyneux *et al.*, 1993; van der Heyde *et al.*, 2006). In addition to parasitized red blood cells (pRBCs), histopathological analysis of the brain of fatal CM cases revealed the presence of leucocytes in the brain microvasculature (Porta *et al.*, 1993; Patnaik *et al.*, 1994; Armah *et al.*, 2005), suggesting that recruitment of these cells to sites of parasite sequestration might result in local inflammation and contribute to disease induction.

Leucocyte trafficking is regulated by a family of chemotactic cytokines called chemokines. The observation that host cells could be found with pRBC in inflamed organs such as brain or placenta attracted interest in investigating trafficking pathways by which inflammatory cells are recruited to target organs in severe malaria. Increased levels of circulating chemokines including CCL4, CXCL4, CXCL8 and CXCL10 have been found to be associated with CM (John *et al.*, 2006, 2008; Armah *et al.*, 2007; Jain *et al.*, 2008; Wilson *et al.*, 2011). Amongst these factors, the CXCR3 binding chemokine CXCL10 has been identified as the most accurate independent predictor of CM mortality in children (Armah *et al.*, 2007; Wilson *et al.*, 2011). In mice, CXCL10 blockade has been shown to protect *P. berghei* ANKA-infected mice from developing CM by reducing recruitment of $CXCR3^+$ leucocytes to the brain (Campanella *et al.*, 2008; Nie *et al.*, 2009). Furthermore, CXCL10 blockade was also shown to improve control of parasitaemia by favouring the accumulation of $CXCR3^+CD4^+$ T follicular helper cells in the spleen, which enhanced antibody responses to infection (Ioannidis *et al.*, 2016).

Consistent with its association with cerebral disease, most malaria studies investigating cellular sources of CXCL10 have focused on brain tissue. High levels of CXCL10 have been detected in the cerebrospinal fluid of children that succumbed to CM (Armah *et al.*, 2007). In mice, CXCL10 expression has been observed in brain endothelial cells (Campanella *et al.*, 2008; Miu *et al.*, 2008; Sorensen *et al.*, 2018), neurons (Campanella *et al.*, 2008), astrocytes (Hanum *et al.*, 2003; Miu *et al.*, 2008) and microglia (Ioannidis *et al.*, 2016). In addition, neutrophils and monocytes that are recruited to the brain during rodent malaria infection (Ioannidis *et al.*, 2016; Sorensen *et al.*, 2018) have been found to be sources of CXCL10 that control the recruitment of $CXCR3^+$ leucocytes involved in the development of CM, suggesting an important role for leucocyte derived CXCL10 in the induction of severe malaria

CAMBRIDGE UNIVERSITY PRESS

disease symptoms. Consistent with this concept, peripheral blood mononuclear cell (PBMC)-derived CXCL10 has been shown to be associated with *P. falciparum*-mediated severe malaria in children (Stanisic *et al.*, 2014). The specific cellular sources of CXCL10 in response to *P. falciparum* are still unknown. In this study, we sought to identify the leucocyte populations in the blood responsible for the induction of CXCL10 in response to *P. falciparum*. Our results show that $CD14^+$ monocytes are the main cellular source of CXCL10 in response to *P. falciparum*. CXCL10 production in response to pRBCs was also found to be stimulated *via* an IFN-γ-dependent mechanism.

Materials and methods

Plasmodium falciparum *culture*

The 3D7 strain of *P. falciparum* was cultured as previously described (Stanisic *et al.*, 2014). Parasites were synchronized by treatment with 5% sorbitol and routinely subjected to gelatin flotation to select for knob-expressing parasites. Trophozoite/schizont stage pRBCs were purified using MACS CS separation columns with a VarioMACS separator (Miltenyi Biotech).

PBMC stimulation

Peripheral blood was collected from healthy volunteers at the Volunteer Blood Donor Registry. PBMCs were then isolated by density gradient centrifugation using Lymphoprep (StemCell Technologies) and cryopreserved in liquid nitrogen until use. Cryopreserved PBMCs were thawed in complete medium (RPMI 1640 with 25 mM HEPES, 10% heat-inactivated foetal bovine serum (HI-FBS; Sigma), 100 U mL^{-1} streptomycin and 100 $\mu g\,mL^{-1}$ penicillin), counted and then seeded into U-bottom 96-well plates (2×10^5 cells per well). PBMCs were stimulated with either uninfected RBCs (uRBCs; 2×10^5 RBCs per well), pRBCs (2×10^5 RBCs per well) or recombinant human IFN-γ (10 ng mL^{-1}; PeproTech) for 24 h at 37°C with 5% CO_2. In some experiments, PBMCs were stimulated in the presence of 20 $\mu g\,mL^{-1}$ anti-IFN-γ (clone NIB42; BD Biosciences) or isotype control antibodies.

Detection of CXCL10 by enzyme-linked immunosorbent assay (ELISA)

The amount of CXCL10 in PBMC culture supernatants was determined by capture ELISA. Briefly, U-bottom 96-well plates were coated with a capture antibody (clone MAB266; R&D systems) in phosphate buffer pH 9.6 by overnight incubation at 4°C. After washing, plates were blocked with 1% BSA (Sigma) in PBS for 1 h at 37°C before incubation with culture supernatants for 2 h at room temperature (RT). Plates were then incubated with biotinylated anti-CXCL10 (clone BAF266; R&D systems) for 2 h at RT, followed by streptavidin-conjugated HRP (Pierce) for 20 min at RT. After washing, bound complexes were detected by reaction with tetramethylbenzidine and H_2O_2 (KPL). Absorbance was measured at 450 nm. Chemokine concentrations were calculated using recombinant CXCL10 (R&D Systems) for the preparation of standard curves.

Flow cytometry

PBMCs were stimulated with uRBCs, pRBCs or IFN-γ for 24 h. Brefeldin A (10 $\mu g\,mL^{-1}$; Sigma) and monensin (2 μM; BD Biosciences) were added to cells for the last 8 h of stimulation. After stimulation, cells were incubated for 10 min on ice with PBS containing 10 mM glucose and 3 mM ethylenediaminetetraacetic acid (EDTA) to detach adherent cells. The cells were then blocked with human IgG (10 $\mu g\,mL^{-1}$; Sigma) for 10 min on ice, washed and then stained with the following antibodies for 30 min on ice: FITC-conjugated anti-human $\gamma\delta$TCR (clone 11F2), PerCP-Cy5.5-conjugated anti-human HLA-DR (clone L234), APC-conjugated anti-human CD123 (clone 6H6), AF700-conjugated anti-human CD19 (HIB19; Biolegend), APC-Cy7-conjugated anti-human CD14 (clone MϕP9), Pacific Blue-conjugated anti-human CD11c (clone 3.9; Biolegend), Qdot 605-conjugated anti-human CD8 (clone 3B5; Invitrogen), Brilliant Violet 650-conjugated anti-human CD4 (clone OKT4; Biolegend), BV711-conjugated anti-human CD16 (clone 3G8) PE Texas Red-conjugated anti-human CD3 (clone UCHT1; Beckman Coulter) and PE-Cy7 conjugated anti-human CD56 (clone B159). All antibodies were purchased from BD Biosciences unless otherwise stated. Aqua amine reactive dye (Life Technologies) was also included for dead cell exclusion. All washes and antibody dilutions were made in FACS buffer [PBS with 0.5% BSA (Sigma) and 2 mM EDTA]. Cells were then fixed in 2% paraformaldehyde and permeabilized using Perm Buffer 2 (BD Biosciences) before intracellular staining with PE-conjugated anti-human CXCL10 (6D4/D6/G2) or an isotype control for 1 h on ice. After staining, cells were washed, re-suspended in FACS buffer and analysed on a BD Fortessa X-1 flow cytometer. Data analysis was performed using FlowJo software (TreeStar, Ashland, OR, USA). A positive response in pRBC-stimulated PBMCs was defined as a frequency of $CXCL10^+$ cells $\geqslant$0.1% after subtraction of the background from uRBC-stimulated cells.

Statistical analysis

Statistical analysis was performed in Prism version 8 (GraphPad Software Inc.). Wilcoxon matched-pairs signed rank tests were used to analyse matched data.

Results

$CD14^+$ monocytes are the main cellular source of CXCL10 in response to P. falciparum

The 3D7 strain of *P. falciparum* has previously been shown to induce CXCL10 production in PBMCs from severe malaria cases in an endemic area of Papua New Guinea (Stanisic *et al.*, 2014). To determine whether this parasite was also able to induce CXCL10 production in PBMCs from malaria-unexposed individuals, PBMCs from healthy donors were stimulated with pRBCs for 24 h and CXCL10 output was determined by ELISA. PBMCs were also stimulated with autologous uRBCs as a negative control, while IFN-γ was included as a positive control. PBMCs from all donors produced CXCL10 in response to pRBC stimulation (Fig. 1A). On average, pRBC-stimulated PBMCs showed a >4-fold increase in CXCL10 levels compared to either media- or uRBC-stimulated cells. Robust CXCL10 responses to IFN-γ were also observed in each donor (Fig. 1B).

To identify the specific cellular sources of CXCL10 in response to *P. falciparum*, PBMCs were stimulated with pRBCs or uRBCs for 24 h and then stained with a panel fluorescently labelled antibodies to assess CXCL10 production in monocytes, dendritic cells, NK cells B cells and various populations of T cells by flow cytometry. The gating strategy used to identify different leucocyte populations is shown in Fig. 1C and D. $CD14^+$ monocytes were identified as a cellular source of CXCL10 in the majority of donors tested. In addition to $CD14^+$ monocytes, CXCL10-producing plasmacytoid DCs (pDCs) were also detected in a small proportion of donors, while CXCL10 production was observed in monocyte-derived

https://doi.org/10.1017/S0031182019001744 Published online by Cambridge University Press



Fig. 1. CD14$^+$ monocytes are the main cellular source of CXCL10 in response to *P. falciparum*. PBMCs were stimulated with uRBCs, pRBCs (A) or IFN-γ (B) for 24 h. Cell culture supernatants were then collected and CXCL10 levels were determined by ELISA. Each bar represents the mean of duplicate wells. Letters indicate individual donors. (C) PBMC were stained with fluorescent antibodies for identification of CD14$^+$ monocytes (CD14$^+$; P1), $\gamma\delta$ T cells (CD3$^+\gamma\delta$ TCR$^+$; P2), CD8$^+$ T cells (CD3$^+$CD8$^+$CD4$^-$; P3), CD4$^+$ T cells (CD3$^+$CD8$^-$CD4$^+$; P4), CD19$^+$ B cells (CD3$^-$CD19$^+$; P5), CD56$^+$ NK cells (CD3$^-$CD19$^-$CD16$^{+/-}$CD56$^+$; P6), pDCs (CD3$^-$HLA-DR$^+$CD14$^-$CD19$^-$CD11c$^-$CD123$^+$; P7) and mDCs (CD3$^-$HLA-DR$^+$CD14$^-$CD19$^-$CD11c$^+$CD127$^+$; P8) by flow cytometry. CXCL10 intracellular staining was evaluated within each gated population as shown in the representative contours (D). The proportion of CXCL10 responders was determined for each cell population (E). A positive response in pRBC-stimulated PBMCs was defined as a frequency of CXCL10$^+$ cells $\geqslant$0.1% after subtraction of the background from uRBC-stimulated cells. (F) Representative histograms showing the level of CXCL10 expression in response to pRBC by CD14$^+$ monocytes, pDCs and mDCs. uRBC-stimulated lymphocytes are included as a background control. Numbers represent the average geometric mean fluorescence intensity (GMFI) for each cell population. The average GMFI of CXCL10 was also determined among all responder donors for each population (G). Bars represent the mean ± s.d., $^{**}P < 0.01$ unpaired *t*-test.

https://doi.org/10.1017/S0031182019001744 Published online by Cambridge University Press



Fig. 2. CXCL10 production in response to *P. falciparum* is IFN-γ-dependent. PBMCs were stimulated with IFN-γ (A), pRBCs (B) or uRBCs (C), or for 24 h in the presence of 20 μg mL^{-1} anti-IFN-γ or isotype control antibodies. Cell culture supernatants were then collected and CXCL10 levels were determined by ELISA. Lines connect the response of individuals to each stimulus in the presence of anti-IFN-γ or isotype control antibodies. Dotted line represents the detection limit of the ELISA. *$P < 0.05$ Wilcoxon matched-pairs signed rank tests.

DCs (mDCs) from one donor (Fig. 1E). CXCL10 expression was not detected in PBMCs from three donors. The median fluorescence intensity of CXCL10 was also determined in each cell population to assess the level of CXCL10 expression (Fig. 1F and 1G). This showed that CXCL10 expression was significantly higher in CD14$^+$ monocytes than pDCs.

PBMC CXCL10 responses to P. falciparum *are IFN-γ-dependent*

Although CXCL10 was initially identified as an IFN-γ-inducible factor, it has been shown that bacterial and viral agonists stimulate its production (Asensio *et al.*, 2001; Park *et al.*, 2006; Bandow *et al.*, 2012; Brownell *et al.*, 2014), suggesting that additional pathways may also contribute to the induction of this chemokine. Consistent with this, both viral infection and the TLR3 agonist polyI:C have been shown to induce CXCL10 production *via* activation of the NF-κB pathway (Spurrell *et al.*, 2005; Brownell *et al.*, 2014). Furthermore, IFN-γ-independent production of CXCL10 has also been reported (Medoff *et al.*, 2002; Cheeran *et al.*, 2003). To determine whether IFN-γ is required for CXCL10 production in PBMCs in response to *P. falciparum*, PBMCs were stimulated with pRBCs in the presence of anti-IFN-γ or isotype control antibodies and CXCL10 output was assessed by using ELISA. Preliminary experiments showed that anti-IFN-γ antibodies inhibit CXCL10 responses in response to IFN-γ in a dose-dependent manner, with >80% neutralization observed at an antibody concentration of 20 μg mL^{-1} (Supplementary Fig. 1). Based on these data, an antibody concentration of 20 μg mL^{-1} was used for subsequent experiments. As expected, CXCL10 production in response to IFN-γ was significantly reduced in the presence of anti-IFN-γ antibodies (Fig. 2A). Notably, IFN-γ neutralization completely abrogated CXCL10 responses to pRBCs (Fig. 2B and C). Thus, *P. falciparum* induces early/innate CXCL10 production in PBMCs from malaria-unexposed donors in an IFN-γ-dependent manner.

Discussion

The CXCR3 chemokine CXCL10 has been shown to be a strong independent predictor of *P. falciparum*-mediated CM mortality in children (Armah *et al.*, 2007; Wilson *et al.*, 2011) and to promote the development of CM in mice (Campanella *et al.*, 2008; Nie *et al.*, 2009). The identity of the cell types responsible for the production of CXCL10 in response to *P. falciparum* in human blood is still unknown. Here we have shown that CD14$^+$ monocytes are the main leucocytic source of CXCL10 in the blood in response to the parasite. As CD16 expression on CD14$^+$ monocytes was not assessed, it remains to be determined which specific monocyte population (i.e. classical, intermediate or non-classical) is responsible for the production of CXCL10 in response to *P. falciparum* (Ziegler-Heitbrock *et al.*, 2010).

Although CXCL10 was initially identified as an IFN-γ-inducible chemokine, it has also been reported that bacterial and viral agonists can stimulate its production from astrocytes (Asensio *et al.*, 2001) and macrophages (Kopydlowski *et al.*, 1999). Our results show that CXCL10 production by PBMCs in response to *P. falciparum* is IFN-γ-dependent. This finding is consistent with previous studies showing that CXCL10 production in human brain endothelial cell-PBMC co-cultures is largely IFN-γ-dependent (Khaw *et al.*, 2013). Previous studies have identified $\gamma\delta$T cells, NK cells and conventional $\alpha\beta$T cells as sources of IFN-γ in *P. falciparum*-stimulated PBMCs (D'Ombrain *et al.*, 2007*a*, 2007*b*), suggesting that IFN-γ production from these cells facilitates down-stream CXCL10 production from CD14$^+$ monocytes in the blood. These studies also found that the IFN-γ response to *P. falciparum* was highly heterogeneous among individuals. Thus, the inability of some donors to produce CXCL10 (Fig. 1E) may reflect poor IFN-γ responsiveness to *P. falciparum* in these individuals.

IFN-γ has been shown to have a dual role in malaria, contributing to both the control of infection and the development of severe disease (King and Lamb, 2015). During the early stages of infection, IFN-γ can help to activate macrophages and enhance their phagocytic activity thereby promoting parasite clearance. IFN-γ also enhances monocyte-mediated antibody-dependent cellular cytotoxicity (Bouharoun-Tayoun *et al.*, 1995). Systemic production of IFN-γ during infection has also been shown to up-regulate ICAM-1 expression on vascular endothelial cells, which promotes parasite sequestration and the development of severe disease (Amani *et al.*, 2000). Here we found that *P. falciparum*-induced IFN-γ results in the production of CXC10, described to be one of the strongest biomarkers of severe malaria, suggesting that in addition to its direct effects triggered by IFN-γ-receptor mediated signalling, down-stream effects activated *via* IFN-γ-mediated chemokine cascades, are also important in the induction of symptomatic malaria. In addition to its well-defined role in leucocyte recruitment, CXCL10 has also been shown to exert anti-angiogenic function (Bodnar *et al.*, 2006; Yates-Binder *et al.*, 2012) and inhibit endothelial cell proliferation (Campanella *et al.*, 2010). Thus, IFN-γ-mediated production of CXCL10 during infection may also inhibit vascular growth and repair required to maintain oxygen and nutrient supply to hypoxic tissues.

Consistent with our findings here, monocytes have also been identified as a major leucocytic source of CXCL10 in CM-susceptible infected mice (Ioannidis *et al.*, 2016; Sorensen *et al.*, 2018). Microglial cells and brain endothelial cells have also been identified as cellular sources of CXCL10 and stable interactions between brain endothelial cells and CD8$^+$ T cells and are thought to be required for the induction of CM in mice (Ioannidis *et al.*, 2014; Sorensen *et al.*, 2018). CXCL10 production by brain-recruited monocytes induces trafficking of CXCR3$^+$ T cells to this site during infection, thereby promoting the development of CM (Ioannidis *et al.*, 2016). Interestingly, monocyte accumulation has been observed in the brain microvasculature of fatal CM cases (Hochman *et al.*, 2015), raising the possibility that a similar process might take place in human CM. Consistent with this hypothesis, high levels of CXCL10 in cerebrospinal fluid have been associated with CM mortality in children (Armah *et al.*, 2007).

https://doi.org/10.1017/S0031182019001744 Published online by Cambridge University Press

This study identified CXCL10 production from unexposed donors suggesting an important role for innate responses in the activation of this pathway. However, it remains to be determined whether additional parasite-specific adaptive responses also contribute to the CXCL10 response to *P. falciparum* in malaria-exposed individuals. Further work with cells from *P. falciparum*-infected individuals will be required to establish if CXCL10 production and its association with the development of severe malaria is further enhanced after activation of other cell populations that have been previously exposed to malaria parasites.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0031182019001744.

Financial support. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council IRIISS and Project Grants 1031212 and 1058665.

Conflict of interest. The authors declare no conflicting interests.

Ethical standards. All experiments were conducted in accordance with the requirements of the Walter and Eliza Hall Institute Human Research Ethics Committee, the National Health and Medical Research Council's National Statement on Ethical Conduct in Human Research and the Helsinki Declaration of 1975, as revised in 2008.

References

Amani V, Vigario AM, Belnoue E, Marussig M, Fonseca L, Mazier D and Renia L (2000) Involvement of IFN-gamma receptor-medicated signaling in pathology and anti-malarial immunity induced by *Plasmodium berghei* infection. *European Journal of Immunology* **30**, 1646–1655.

Armah H, Dodoo AK, Wiredu EK, Stiles JK, Adjei AA, Gyasi RK and Tettey Y (2005) High-level cerebellar expression of cytokines and adhesion molecules in fatal, paediatric, cerebral malaria. *Annals of Tropical Medicine & Parasitology* **99**, 629–647.

Armah HB, Wilson NO, Sarfo BY, Powell MD, Bond VC, Anderson W, Adjei AA, Gyasi RK, Tettey Y, Wiredu EK, Tongren JE, Udhayakumar V and Stiles JK (2007) Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. *Malaria Journal* **6**, 147.

Asensio VC, Maier J, Milner R, Boztug K, Kincaid C, Moulard M, Phillipson C, Lindsley K, Krucker T, Fox HS and Campbell IL (2001) Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes *in vivo* and *in vitro*. *Journal of Virology* **75**, 7067–7077.

Bandow K, Kusuyama J, Shamoto M, Kakimoto K, Ohnishi T and Matsuguchi T (2012) LPS-induced chemokine expression in both MyD88-dependent and -independent manners is regulated by Cot/Tpl2-ERK axis in macrophages. *FEBS Letters* **586**, 1540–1546.

Bodnar RJ, Yates CC and Wells A (2006) IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation *via* inhibition of calpain. *Circulation Research* **98**, 617–625.

Bouharoun-Tayoun H, Oeuvray C, Lunel F and Druilhe P (1995) Mechanisms underlying the monocyte-mediated antibody-dependent killing of *Plasmodium falciparum* asexual blood stages. *Journal of Experimental Medicine* **182**, 409–418.

Brownell J, Bruckner J, Wagoner J, Thomas E, Loo YM, Gale Jr M, Liang TJ and Polyak SJ (2014) Direct, interferon-independent activation of the CXCL10 promoter by NF-kappaB and interferon regulatory factor 3 during hepatitis C virus infection. *Journal of Virology* **88**, 1582–1590.

Campanella GSV, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, Manice LA, Colvin RA and Lustert AD (2008) Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. *Proceedings of the National Academy of Sciences of the USA* **105**, 4814–4819.

Campanella GS, Colvin RA and Luster AD (2010) CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. *PLoS ONE* **5**, e12700.

Cheeran MC, Hu S, Sheng WS, Peterson PK and Lokensgard JR (2003) CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10. *Journal of Virology* **77**, 4502–4515.

D'Ombrain MC, Hansen DS, Simpson KM and Schofield L (2007a) Gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to *Plasmodium falciparum* malaria. *European Journal of Immunology* **37**, 1864–1873.

D'Ombrain MC, Voss TS, Maier AG, Pearce JA, Hansen DS, Cowman AF and Schofield L (2007b) *Plasmodium falciparum* erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma. *Cell Host & Microbe* **2**, 130–138.

Grau GE, Mackenzie CD, Carr RA, Redard M, Pizzolato G, Allasia C, Cataldo C, Taylor TE and Molyneux ME (2003) Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. *Journal of Infectious Diseases* **187**, 461–466.

Hanum S, Hayano M and Kojima S (2003) Cytokine and chemokine responses in a cerebral malaria-susceptible or -resistant strain of mice to *Plasmodium berghei* ANKA infection: early chemokine expression in the brain. *International Immunology* **15**, 633–640.

Hochman SE, Madaline TF, Wassmer SC, Mbale E, Choi N, Seydel KB, Whitten RO, Varughese J, Grau GE, Kamiza S, Molyneux ME, Taylor TE, Lee S, Milner Jr DA and Kim K (2015) Fatal pediatric cerebral malaria is associated with intravascular monocytes and platelets that are increased with HIV co-infection. *MBio* **6**, 1–15. doi: 10.1128/mBio.01390-15. doi: 10.1128/mBio.01390-15.

Ioannidis LJ, Nie CQ and Hansen DS (2014) The role of chemokines in severe malaria: more than meets the eye. *Parasitology* **141**, 602–613.

Ioannidis LJ, Nie CQ, Ly A, Ryg-Cornejo V, Chiu CY and Hansen DS (2016) Monocyte- and neutrophil-derived CXCL10 impairs efficient control of blood-stage malaria infection and promotes severe disease. *Journal of Immunology* **196**, 1227–1238.

Jain V, Armah HB, Tongren JE, Ned RM, Wilson NO, Crawford S, Joel PK, Singh MP, Nagpal AC, Dash AP, Udhayakumar V, Singh N and Stiles JK (2008) Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. *Malaria Journal* **7**, 83.

John CC, Opika-Opoka R, Byarugaba J, Idro R and Boivin MJ (2006) Low levels of RANTES are associated with mortality in children with cerebral malaria. *Journal of Infectious Diseases* **194**, 837–845.

John CC, Park GS, Sam-Agudu N, Opoka RO and Bolvin MJ (2008) Elevated serum levels of IL-1rα in children with *Plasmodium falciparum* malaria are associated with increased severity of disease. *Cytokine* **41**, 204–208.

Khaw LT, Ball HJ, Golenser J, Combes V, Grau GE, Wheway J, Mitchell AJ and Hunt NH (2013) Endothelial cells potentiate interferon-gamma production in a novel tripartite culture model of human cerebral malaria. *PLoS ONE* **8**, e69521.

King T and Lamb T (2015) Interferon-gamma: the Jekyll and Hyde of malaria. *PLoS Pathogens* **11**, e1005118.

Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA and Vogel SN (1999) Regulation of macrophage chemokine expression by lipopolysaccharide *in vitro* and *in vivo*. *Journal of Immunology* **163**, 1537–1544.

Medoff BD, Sauty A, Tager AM, Maclean JA, Smith RN, Mathew A, Dufour JH and Luster AD (2002) IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. *Journal of Immunology* **168**, 5278–5286.

Miller LH, Baruch DI, Marsh K and Doumbo OK (2002) The pathogenic basis of malaria. *Nature* **415**, 673–679.

Miu J, Mitchell AJ, Muller M, Carter SL, Manders PM, McQuillan JA, Saunders BM, Ball HJ, Lu B, Campbell LL and Hunt NH (2008) Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. *Journal of Immunology* **180**, 1217–1230.

Molyneux ME, Engelmann H, Taylor TE, Wirima JJ, Aderka D, Wallach D and Grau GE (1993) Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria. *Cytokine* **5**, 604–609.

Murphy SC and Breman JG (2001) Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. *American Journal of Tropical Medicine and Hygiene* **64**, 57–67.

Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, Crabb BS, Heath WR, Engwerda CR, Hickey MJ, Schofield L and Hansen DS

(2009) IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. *PLoS Pathogens* **5**, e1000369.

Park C, Lee S, Cho IH, Lee HK, Kim D, Choi SY, Oh SB, Park K, Kim JS and Lee SJ (2006) TLR3-mediated Signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression. *Glia* **53**, 248–256.

Patnaik JK, Das BS, Mishra SK, Mohanty S, Satpathy SK and Mohanty D (1994) Vascular clogging, mononuclear cell margination, and enhanced vascular permeability in the pathogenesis of human cerebral malaria. *American Journal of Tropical Medicine and Hygiene* **51**, 642–647.

Porta J, Carota A, Pizzolato GP, Wildi E, Widmer MC, Margairaz C and Grau GE (1993) Immunopathological changes in human cerebral malaria. *Clinical Neuropathology* **12**, 142–146.

Sorensen EW, Lian J, Ozga AJ, Miyabe Y, Ji SW, Bromley SK, Mempel TR and Luster AD (2018) CXCL10 stabilizes T cell-brain endothelial cell adhesion leading to the induction of cerebral malaria. *JCI Insight* **3**, 1–19. doi: 10.1172/jci.insight.98911.

Spurrell JC, Wiehler S, Zaheer RS, Sanders SP and Proud D (2005) Human airway epithelial cells produce IP-10 (CXCL10) *in vitro* and *in vivo* upon rhinovirus infection. *American Journal Of Physiology. Lung Cellular And Molecular Physiology* **289**, L85–L95.

Stanisic DI, Cutts J, Eriksson E, Fowkes FJ, Rosanas-Urgell A, Siba P, Laman M, Davis TM, Manning L, Mueller I and Schofield L (2014) $\Gamma\delta$ T cells and $CD14^{+}$ monocytes are predominant cellular sources of cytokines and chemokines associated with severe malaria. *Journal of Infectious Diseases* **210**, 295–305.

Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosiko NM, Lewallen S, Liomba NG and Molyneux ME (2004) Differentiating the pathologies of cerebral malaria by postmortem parasite counts. *Nature Medicine* **10**, 143–145.

Turner GD, Morrison H, Jones M, Davis TM, Looareesuwan S, Buley ID, Gatter KC, Newbold CI, Pukritayakamee S, Nagachinta B, White NJ and Berendt AR (1994) An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. *American Journal of Pathology* **145**, 1057–1069.

van der Heyde HC, Nolan J, Combes V, Gramaglia I and Grau GE (2006) A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. *Trends in Parasitology* **22**, 503–508.

Walter PR, Garin Y and Blot P (1982) Placental pathologic changes in malaria. A histologic and ultrastructural study. *American Journal of Pathology* **109**, 330–342.

WHO (2016) *World Malaria Report 2016*. Geneva: World Health Organisation.

Wilson NO, Jain V, Roberts CE, Lucchi N, Joel PK, Singh MP, Nagpal AC, Dash AP, Udhayakumar V, Singh N and Stiles JK (2011) CXCL4 And CXCL10 predict risk of fatal cerebral malaria. *Disease Markers* **30**, 39–49.

Yates-Binder CC, Rodgers M, Jaynes J, Wells A, Bodnar RJ and Turner T (2012) An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. *PLoS ONE* **7**, e40812.

Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM and Lutz MB (2010) Nomenclature of monocytes and dendritic cells in blood. *Blood* **116**, e74–e80.

https://doi.org/10.1017/S0031182019001744 Published online by Cambridge University Press